Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Otilonium→

Otilonium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
105360-89-2
Molecular formula
C29H43N2O4+
Molecular weight
483.7 g/mol
Drug class
Quaternary ammonium gastrointestinal antispasmodicsmooth-muscle calcium-channel blocker
Mechanism of action
Acts locally in the intestinal wall and inhibits gastrointestinal smooth-muscle contraction, mainly by blocking L-type calcium-channel activity and interfering with intracellular calcium mobilisation. It also modulates selected muscarinic and tachykinin receptor pathways.
Indications / reported uses
  • Symptomatic treatment of abdominal pain and intestinal spasm associated with irritable bowel syndrome.

Sources: https://pubmed.ncbi.nlm.nih.gov/29732965/ · https://pubmed.ncbi.nlm.nih.gov/25057296/ · https://www.unipharma-sy.com/Product/594 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Otilonium Environmental Risk Assessment (ERA) (the Otilonium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.